CClinicalTrials.gg
WithdrawnNCT00298064Updated Jul 5, 2023

Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer

An interventional study of Tissue Repository in Cervical Cancer and Cervix, sponsored by University of New Mexico. Withdrawn at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2023-07-05.

Sponsored by University of New Mexico · Not applicable and Interventional

Phase
Not applicable
Study type
Interventional
Enrollment
0
Sex
Female
01

Study summary

The Tissue Repository will search for cases, pull slides, Paraffin-embedded tissue (PET) blocks.

Read the detailed description

This study is done to gather preliminary data for determining the best way to test EGFR expression in patients with cervical cancer who will receive treatment with EGFR inhibitors in the future.

This study is designed to obtain preliminary data of genomic and phenotypic alterations of the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic (over-expression, amplification, point mutations, etc.) and phenotypic alterations of other transduction pathways interacting with the EGFR pathway.

02

Conditions studied

  • Cervical Cancer
  • Cervix

Keywords

  • Cervical cancer
  • EGFR
  • cervical
  • genomic
  • DNA
  • markers
  • prognostic
  • gene
  • epidermal growth factor
03

In context

Uterine Cervical Neoplasms

1,881 studies on the registry are indexed under Uterine Cervical Neoplasms; 567 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

University of New Mexico is the lead sponsor of 306 studies on the registry; 28 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 23 (92%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Samples from patients diagnosed with HG-SIL (n=300) and CC (n=300) with a follow-up of at least 24 months, existing at the Department of Pathology will be retrieved by the Tissue Repository, de-identified them and provided with code numbers that will not be linked to patient's data.

Exclusion criteria

Exclusion Criteria:

  • None Specified.
05

Study design

Phase
Not applicable
Enrollment
0 participants (actual)

Interventions

  • GeneticTissue Repository
06

Study locations

1 site
  • University of New Mexico
    Albuquerque, New Mexico 87131, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00298064
Lead sponsor
University of New Mexico
Responsible party
Sponsor
First posted
Mar 1, 2006
Start date
Dec 2005
Primary completion
Dec 2005
Completion
Dec 2005
Last update
Jul 5, 2023

Study contacts

Claire Verschraegen, MD
principal investigator · University of New Mexico

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion